🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆ Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆
Clinical Trials in Poland / NCT07768423
Recruiting Not applicable

The Impact of Omega-3 Fatty Acid Supplementation on the Composition of Erythrocyte Membranes in Athletes

NCT07768423 · tracked via the Priya Life Science Poland tracker
Phase
Not applicable
Started
2025-01-07
Last updated
2026-08-17

Condition(s) studied

Physical PerformanceCognitive FunctionSports Nutrition

Investigational drug(s) / intervention(s)

EPA + DHA supplementsPlacebo

EPA + DHA supplements: Participants will randomly assigned to the supplemented group. The supplement will be administered in a dose of 4 capsules twice a day for 4 weeks. Daily dose will contain 3500mg EPA + DHA

Placebo: Participants will randomly assigned to the Placebo group. The placebo will be administered in a dose of 4 capsules twice a day for 4 weeks. Daily dose will contain 3500mg MCT.

Study summary

The aim of this study is to evaluate the effects of omega-3 fatty acid supplementation on the Omega-3 Index, erythrocyte membrane composition, cognitive function, hormonal profile, speed, endurance performance, and hematological parameters in competitive athletes aged 16-35 years.

Eligibility

Sex
ALL
Min age
16 Years
Max age
35 Years
Healthy volunteers
Accepted
\*\*Inclusion Criteria:\*\* * Male competitive soccer players aged 16-35 years. * Regular participation in organized soccer training and competition. * A minimum of 6 years of systematic soccer training experience. * Participation in regular team training during the study period. * Habitual mixed diet. * Ability and willingness to maintain usual dietary habits and training load throughout the 4-week intervention. * Written informed consent provided by the participant. * For participants under 18 years of age, written informed consent provided by a parent or legal guardian and assent provided by the participant. \*\*Exclusion Criteria:\*\* * Current use of omega-3 fatty acid supplements or fish-oil products. * Use of omega-3 supplements within the 3 months preceding enrollment. * Known allergy or hypersensitivity to fish, seafood, fish oil, or any ingredient of the study supplements. * Diagnosed cardiovascular, metabolic, endocrine, gastrointestinal, neurological, inflammatory, autoimmune, or hematological disease. * Acute infection, injury, or illness that could affect participation in training or study assessments. * Use of medications or dietary supplements that could influence lipid metabolism, inflammatory status, hormonal profile, blood coagulation, cognitive function, or physical performance. * Regular use of anticoagulant or antiplatelet medication. * Significant change in diet, training volume, or supplementation during the study period. * Failure to comply with the supplementation protocol or attendance requirements. * Participation in another clinical or nutritional intervention study during the study period.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Jerzy Kukuczka Academy of Physical Education in Katowice Katowice Mikolowska 72a Recruiting

More The Jerzy Kukuczka Academy of Physical Education in Katowice trials in Poland

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07768423 on ClinicalTrials.gov ↗ ← All trials in Poland